Acoramidis Cuts AFib Hospitalizations in ATTR Amyloidosis

In this interview, CardioNerds Fellows Drs. Georgia Vasilakis Tsatiris and Anna Radhakrishnan ask Dr. Kevin Alexander to clarify differences between the modified intention-to-treat (MITT) and safety populations in a clinical trial analyzing acoramidis in patients with transthyretin cardiac amyloidosis. Dr. Alexander explains that the MITT group was used for primary analysis and included adjudicated cardiovascular hospitalizations, while the larger safety cohort included additional patients and event reporting from clinical sites, including outpatient cases. He highlights consistent findings across both groups, showing that acoramidis significantly reduced atrial fibrillation (AFib)–related hospitalizations by 43% in the MITT group and lowered AFib/atrial flutter incidence by 17% in the safety cohort.